BC Innovations | Mar 17, 2016
Distillery Therapeutics

Therapeutics: Jumonji domain containing 1C (JMJD1C)

Cancer INDICATION: Acute myelogenous leukemia (AML) Mouse studies suggest inhibiting JMJD1C could help treat AML. In bone marrow and spleen leukemia-initiating stem cells from a mouse model of AML, levels of JMJD1C were higher than...
Items per page:
1 - 1 of 1